Kaken Pharmaceutical Co., Ltd.

TSE:4521 Stock Report

Market Cap: JP¥144.5b

Kaken Pharmaceutical Valuation

Is 4521 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 4521 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 4521 (¥3810) is trading below our estimate of future cash flow value (¥4804.17)

Significantly Below Future Cash Flow Value: 4521 is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4521?

Key metric: As 4521 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4521. This is calculated by dividing 4521's market cap by their current earnings.
What is 4521's PE Ratio?
PE Ratio67.3x
EarningsJP¥2.14b
Market CapJP¥144.47b

Price to Earnings Ratio vs Peers

How does 4521's PE Ratio compare to its peers?

The above table shows the PE ratio for 4521 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.3x
4547 Kissei Pharmaceutical
12x0.70%JP¥161.7b
4534 Mochida Pharmaceutical
14.2xn/aJP¥110.2b
4553 Towa Pharmaceutical
34.5x20.25%JP¥185.6b
4887 Sawai Group Holdings
16.5x11.56%JP¥193.6b
4521 Kaken Pharmaceutical
67.3x15.16%JP¥144.5b

Price-To-Earnings vs Peers: 4521 is expensive based on its Price-To-Earnings Ratio (67.3x) compared to the peer average (19.3x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does 4521's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
4521 67.3xIndustry Avg. 16.2xNo. of Companies5PE01224364860+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4521 is expensive based on its Price-To-Earnings Ratio (67.3x) compared to the JP Pharmaceuticals industry average (16.2x).

Price to Earnings Ratio vs Fair Ratio

What is 4521's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4521 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio67.3x
Fair PE Ratio21.8x

Price-To-Earnings vs Fair Ratio: 4521 is expensive based on its Price-To-Earnings Ratio (67.3x) compared to the estimated Fair Price-To-Earnings Ratio (21.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4521 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥3,810.00
JP¥4,350.00
+14.17%
14.58%JP¥5,300.00JP¥3,600.00n/a4
Jun ’27JP¥3,895.00
JP¥4,325.00
+11.04%
13.81%JP¥5,200.00JP¥3,600.00n/a4
May ’27JP¥4,075.00
JP¥4,375.00
+7.36%
13.17%JP¥5,200.00JP¥3,600.00n/a4
Apr ’27JP¥4,230.00
JP¥4,375.00
+3.43%
13.17%JP¥5,200.00JP¥3,600.00n/a4
Mar ’27JP¥4,435.00
JP¥4,400.00
-0.79%
17.01%JP¥5,400.00JP¥3,600.00n/a3
Feb ’27JP¥4,065.00
JP¥4,400.00
+8.24%
17.01%JP¥5,400.00JP¥3,600.00n/a3
Jan ’27JP¥4,015.00
JP¥4,400.00
+9.59%
17.01%JP¥5,400.00JP¥3,600.00n/a3
Dec ’26JP¥3,830.00
JP¥4,500.00
+17.49%
20.00%JP¥5,400.00JP¥3,600.00n/a2
Nov ’26JP¥3,665.00
JP¥4,550.00
+24.15%
20.88%JP¥5,500.00JP¥3,600.00n/a2
Oct ’26JP¥3,620.00
JP¥4,550.00
+25.69%
20.88%JP¥5,500.00JP¥3,600.00n/a2
Sep ’26JP¥3,817.00
JP¥4,550.00
+19.20%
20.88%JP¥5,500.00JP¥3,600.00n/a2
Aug ’26JP¥3,984.00
JP¥4,600.00
+15.46%
21.74%JP¥5,600.00JP¥3,600.00n/a2
Jul ’26JP¥3,791.00
JP¥4,600.00
+21.34%
21.74%JP¥5,600.00JP¥3,600.00n/a2
Jun ’26JP¥3,844.00
JP¥4,600.00
+19.67%
21.74%JP¥5,600.00JP¥3,600.00JP¥3,895.002
May ’26JP¥4,041.00
JP¥4,850.00
+20.02%
25.77%JP¥6,100.00JP¥3,600.00JP¥4,075.002
Apr ’26JP¥4,489.00
JP¥4,850.00
+8.04%
25.77%JP¥6,100.00JP¥3,600.00JP¥4,230.002
Mar ’26JP¥4,552.00
JP¥4,850.00
+6.55%
25.77%JP¥6,100.00JP¥3,600.00JP¥4,435.002
Feb ’26JP¥4,220.00
JP¥4,850.00
+14.93%
25.77%JP¥6,100.00JP¥3,600.00JP¥4,065.002
Jan ’26JP¥4,513.00
JP¥4,850.00
+7.47%
25.77%JP¥6,100.00JP¥3,600.00JP¥4,015.002
Dec ’25JP¥4,323.00
JP¥4,850.00
+12.19%
25.77%JP¥6,100.00JP¥3,600.00JP¥3,830.002
JP¥4.35k
Fair Value
12.4% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/18 10:07
End of Day Share Price 2026/06/18 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kaken Pharmaceutical Co., Ltd. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kazuaki HashiguchiDaiwa Securities Co. Ltd.
Junya YamazakiJefferies LLC
Toshiyuki IwataMizuho Securities Co., Ltd.